IRIS
LIAKOULI, Vasiliki
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.089
EU - Europa 3.384
AS - Asia 3.028
SA - Sud America 302
Continente sconosciuto - Info sul continente non disponibili 161
AF - Africa 46
OC - Oceania 11
Totale 13.021
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.982
SG - Singapore 1.338
IT - Italia 747
IE - Irlanda 693
CN - Cina 674
RU - Federazione Russa 530
SE - Svezia 361
TR - Turchia 321
HK - Hong Kong 281
DE - Germania 270
BR - Brasile 259
VN - Vietnam 237
UA - Ucraina 196
GB - Regno Unito 195
FR - Francia 141
FI - Finlandia 89
CA - Canada 70
NL - Olanda 51
IN - India 44
BE - Belgio 35
BD - Bangladesh 31
JP - Giappone 28
ZA - Sudafrica 21
PL - Polonia 16
MX - Messico 15
ES - Italia 13
ID - Indonesia 12
AR - Argentina 8
CO - Colombia 8
CZ - Repubblica Ceca 8
EC - Ecuador 8
IQ - Iraq 7
JM - Giamaica 7
SA - Arabia Saudita 7
VE - Venezuela 7
AU - Australia 6
EU - Europa 6
MY - Malesia 6
LT - Lituania 5
MA - Marocco 5
NZ - Nuova Zelanda 5
TN - Tunisia 5
UZ - Uzbekistan 5
HN - Honduras 4
JO - Giordania 4
LB - Libano 4
PK - Pakistan 4
PT - Portogallo 4
AT - Austria 3
BO - Bolivia 3
CL - Cile 3
CR - Costa Rica 3
DZ - Algeria 3
EE - Estonia 3
EG - Egitto 3
HU - Ungheria 3
IL - Israele 3
IR - Iran 3
KZ - Kazakistan 3
AL - Albania 2
BA - Bosnia-Erzegovina 2
CH - Svizzera 2
CI - Costa d'Avorio 2
CW - ???statistics.table.value.countryCode.CW??? 2
DK - Danimarca 2
GR - Grecia 2
HR - Croazia 2
KE - Kenya 2
KR - Corea 2
LU - Lussemburgo 2
NP - Nepal 2
PE - Perù 2
PH - Filippine 2
PY - Paraguay 2
RO - Romania 2
SN - Senegal 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
KW - Kuwait 1
MD - Moldavia 1
MK - Macedonia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PR - Porto Rico 1
SC - Seychelles 1
SI - Slovenia 1
Totale 12.868
Salva come PNG Salva come JPEG
Città #
Jacksonville 775
Singapore 736
Chandler 723
Dublin 693
San Jose 632
Ashburn 454
Council Bluffs 301
Dallas 300
Hong Kong 276
Santa Clara 261
Boardman 230
Izmir 201
The Dalles 151
New York 147
Ann Arbor 135
Nanjing 121
Milan 118
Beijing 112
Moscow 103
Wilmington 102
Lawrence 101
Princeton 101
San Mateo 93
Ho Chi Minh City 80
L'aquila 72
Los Angeles 70
Rome 64
Woodbridge 52
Dearborn 49
Lauterbourg 47
Hanoi 43
Nanchang 43
Brussels 35
Amsterdam 33
Munich 33
Verona 33
Naples 32
Shenyang 30
São Paulo 29
Seattle 28
Tokyo 28
Mountain View 27
Hefei 26
Helsinki 25
Kunming 25
Shanghai 24
Jiaxing 23
Hebei 22
Dong Ket 20
Atlanta 19
Des Moines 19
Frankfurt am Main 19
Phoenix 19
Changsha 18
Montreal 18
Columbus 17
Las Vegas 17
San Francisco 17
Chicago 16
Orem 16
Johannesburg 15
Tianjin 15
Bari 14
Bologna 14
L’Aquila 14
Miano 14
Warsaw 14
Jinan 13
Houston 12
Philadelphia 12
Brooklyn 11
Toronto 11
Zhengzhou 11
Florence 10
Guangzhou 10
Manchester 10
Stockholm 10
Chennai 9
Da Nang 9
Denver 9
Haiphong 9
London 9
Ningbo 9
Palermo 9
Pescara 9
Pune 9
Rio de Janeiro 9
Grafing 8
Biên Hòa 7
Falkenstein 7
Hangzhou 7
Kingston 7
Mumbai 7
Norwalk 7
Nuremberg 7
Washington 7
Afragola 6
Ankara 6
Bremen 6
Brno 6
Totale 8.442
Salva come PNG Salva come JPEG
Nome #
Studio dell’espressione della chemochina SDF-1 e del suo recettore CXCR4 nella cute e nelle cellule endoteliali microvascolari di pazienti affetti da sclerosi sistemica (SSc). 220
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 171
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 170
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 170
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 169
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 168
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 167
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 165
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 165
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 164
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 158
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 151
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 150
Cardiovascular disease in primary sjögren’s syndrome 149
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 149
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 148
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 145
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 143
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 143
The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis 143
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6 142
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosi 142
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 141
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 140
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 140
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 140
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 138
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 136
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 136
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 136
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 136
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 135
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 134
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 132
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 131
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 130
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 130
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 129
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 128
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 128
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 127
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 127
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 126
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. 126
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 126
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 126
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 126
Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis 125
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population. 125
Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. 124
Variations of neuronal nitric oxide synthase in systemic sclerosis skin 123
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 123
Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor 123
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis 122
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 122
Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. 121
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study 120
Interstitial lung disease in systemic sclerosis: current and future treatment. 120
Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. 119
The Vessels Contribute to Fibrosis in Systemic Sclerosis 118
Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial 118
FAS -670 gene promoter polymorphism confers susceptibility to systemic sclerosis 117
Cellular players in angiogenesis during the course of systemic sclerosis. 117
CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS 117
Differential expression of SDF-1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis: pathogenetic implication. 116
IMPAIREMENT OF ENDOTHELIAL DIFFERENTIATION FROM MESENCHYMAL STEM CELLS (MSC) IN SYSTEMIC SCLEROSIS (SSC): A NEW TOOL IN PATHOGENETIC MECHANISM 116
Surface expression of fractalkine receptor (CX3CR1) on CD4+/CD28-. T cells in RA patients and correlation with atherosclerotic damage 114
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosis 113
SAT0489 Biologic Therapies and Infections in The Daily Practice: A Study on Historical Cohort from 3 Italian Rheumatologic Units 113
Virtual skin biopsy by optical coherence tomography: the first quantitative imaging biomarker for scleroderma. 113
Laboratory assessment in patients with suspected rheumatic musculoskeletal diseases: challenges, pitfalls and perspectives 113
Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). 113
Decreased Expression of Angiopoetin 1 on Perivascular Mesenchymal Stem Cells from Ssc Patients Induces an Anti Angiogenetic Effect, when Co-cultured with Endothelial Cells 112
FRI0414 Evaluation of a novel multi-analyte assay for the detection of autoantibodies in the diagnosis of systemic sclerosis 111
Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications 110
Methotrexate: an old new drug in autoimmune disease. 110
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis 110
Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? 109
Caveolin-1 orchestrates vascular endothelial growth factor (VEGF) signaling control of angiogenesis during systemic sclerosis (SSC) 108
Adipose stromal vascular fraction and regenerative therapy in SSc: Response to the article by Magalon et al 108
SDF-1 expression in the skin of SSc patients. 107
Pathogenesis of the endothelial damage and related factors. 106
Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with sjogren’s syndrome 106
Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study 104
THU0582 Prognostic Factors of Macrophage Activation Syndrome in Adults: Analysis of 40 Cases in 2 Tertiary Referral Centers 103
Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. 103
Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis 101
Interstitial lung disease in systemic sclerosis: Pathophysiology and therapy 101
Senescent bone marrow mesenchymal stem cells (BM-MSCS) preserve their immune-regulatory effect on t cells during systemic sclerosis (SSC). 99
Mesenchymal stem cells transplantation in Systemic Sclerosis: comment on the article by ATJ Maria et al 99
Tocilizumab for the treatment of adult-onset Still's disease: Results from a case series 98
THE OCCURRENCE OF SUBCLINICAL AND CLINICAL ATHEROSCLEROSIS IN RHEUMATOID ARTHRITIS, RESULTS FROM THE 3-YEAR, MULTICENTER, PROSPECTIVE, OBSERVATIONAL, GIRRCS STUDY 97
THE IL-33/ST2 PATHWAY IN SYSTEMIC SCLEROSIS 96
ASSOCIATION OF FAS-G670A GENE POLYMORPHISM WITH SYSTEMIC SCLEROSIS 96
Modificazioni della nitrossido-sintasi neuronale (nNOS) nella cute dei pazienti con sclerosi sistemica (SSc). 94
Endothelial Progenitor Cells (EPC) characterization in systemic sclerosis (SSc) patients 92
Angiogenic cytokines and growth factors in systemic sclerosis. 91
VASCULAR SMOOTH MUSCLE CELLS (SMC) PROGENITORS: NEW PLAYERS IN SYSTEMIC SCLEROSIS (SSC) DEFECTIVE VESSEL REGENERATION. 89
Potential of stem cells in the treatment of rheumatic disease 89
 Epidermal growth factor-like domain 7 (EGFL7) in skin of systemic sclerosis 86
Totale 12.596
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.031
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.031
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022397 0 0 0 53 13 10 9 27 44 35 47 159
2022/20232.035 153 127 32 238 160 215 4 118 882 15 63 28
2023/2024484 71 35 28 51 50 158 10 25 1 22 9 24
2024/20251.974 39 38 187 62 339 154 224 149 432 82 142 126
2025/20263.607 235 346 144 428 405 275 648 136 310 390 240 50
2026/20271.254 130 100 331 693 0 0 0 0 0 0 0 0
Totale 13.021